[Secondary prevention of opportunistic infections in HIV-infected patients].
Asencio Marchante
R
R
Grupo para el estudio de la Hepatitis Vírica y SIDA, Hospital Universitario Virgen del Rocío, Sevilla.
Lissen Otero
E
E
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000981:Antiprotozoal Agents / Q000008:administration & dosage; D000995:Antitubercular Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000517:prevention & control; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage; D015774:Ganciclovir / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000517:prevention & control; D011739:Pyrimethamine / Q000008:administration & dosage; D012008:Recurrence; D017828:Rifabutin / Q000008:administration & dosage; D013411:Sulfadiazine / Q000008:administration & dosage; D013420:Sulfamethoxazole / Q000008:administration & dosage; D014123:Toxoplasmosis / Q000188:drug therapy / Q000517:prevention & control; D014295:Trimethoprim / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000981:Antiprotozoal Agents; D000995:Antitubercular Agents; D000998:Antiviral Agents; D013411:Sulfadiazine; D017828:Rifabutin; D004977:Ethambutol; D014295:Trimethoprim; D017291:Clarithromycin; D013420:Sulfamethoxazole; D015774:Ganciclovir; D002955:Leucovorin; D011739:Pyrimethamine